Three Experienced Organizations, One Committed Pursuit, Bringing Hope To Millions.
 

Other dedicated researchers and scientists working to advance our therapeutic solutions:

 

 

Name
 
Jie Zheng Ph.D
Xiaoping Du, M.D.
Donald L. Ewert, Ph.D.
Jianzhong Lu, M.S., Ph.D.
Satish Kuriyavar, Ph.D.
Ning Hu, M.D., Ph.D.
Weihua Cheng, B.S.
Wei Li,  MD,  MS
Charles Stewart, Ph.D.

Chairman and Chief Executive Officer

As an experienced team leader Mr. Karlman coalesces a unique blend of business acumen and interpersonal skill sets. He displays cross-disciple entrepreneurial thinking, which results in creative solutions that span the strategic to the tactical. He creates and communicates objectives clearly, analyzes data thoroughly and extracts emerging trends accurately. Mr. Karlman is a Rule SEC 501 investor. During his career on C-level teams he has raised in excess of $84M of investment capital.

 

 

Specific skill sets:

• Consistency in consultative executive leadership, ability to multitask, negotiating difficult agreements, and building relationships while delivering quality results.
 
• He brings balance, focus, and experience to leading entrepreneurial groups, distilling seminal issues, and making difficult decisions.

 

• With keen sense, and experience, in maximizing leveraged impact, he actively contributes creative revenue acceleration strategies and risk mitigation solutions to vexing business challenges.

 

• Strict and vigilant budget management that maximizes return on resources.

 

• Maintains a clear conviction to the fiduciary responsibilities required of senior leaders in an organization.
Chief Medical Officer
Richard "Rick" Kopke, M.D., FACS, retired from the U.S. Army after serving for 22 years, and is currently practicing otology at the Otologic Medical Clinic in Oklahoma City as well as conducting research at the Hough Ear Institute in the areas of, preventing noise induced hearing loss, inner ear drug delivery, and auditory hair cell regeneration.  He is a Clinical Professor in the Department of Otorhinolaryngology-Head and Neck Surgery and an Adjunct Professor at the University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation.  He has written over 50 peer-reviewed articles, has been awarded patents, and has conducted clinical trials involving noise-induced hearing loss.

He was awarded the Edmund Prince Fowler Award for seminal research on preventing noise-induced hearing loss with drugs by the Triologic Society. He has built an international reputation as an expert in the field of inner ear medicine and noise-induced hearing loss.

He also received the Legion of Merit, one of our country's highest military honors. Dr. Kopke is board certified in otolaryngology and has subspecialty certification in neurotology.
Chief Science Officer
Robert Floyd, PhD has conducted NIH-funded basic biomedical research for over 35 years at the Oklahoma Medical Research Foundation (OMRF). For 20 years he was head of the Free Radical Biology and Aging Research department and helped to recruit several highly accomplished scientists in this field of research to the OMRF and the Oklahoma University Health Sciences Center. He is considered an international expert on the role of free radicals and reactive oxygen species in age related diseases and has won several awards including the Glenn Foundation for medical Research Award (1992), Top Award and Gold Medal of the American Aging Association (1996) and The Discovery Award of the Society for Free Radical Biology and Medicine (2007). He has pioneered in patented discoveries and translational science on the use of nitrones as therapeutics for the treatment of ischemic stroke as well as anti-cancer agents. This research resulted in collaboration efforts leading to the founding of Centaur Pharmaceuticals (1992) and Onconos LLC respectively. In the 8 yr history of Centaur Pharmaceuticals he served as a member of the Board of Directors and Chairman of the Scientific Advisory Board of this biotech company which partnered with AstraZeneca to develop NXY-059 for the treatment of stroke that underwent extensive phase I, II and III clinical trials. Over the last 5 years, he and Dr. Rick Kopke have collaborated in the development of the use of antioxidants for the treatment of noise-induced hearing loss in animal models. Their research has led to the discovery that specific nitrones and NAC act synergistically to prevent noise-induced hearing loss. These patented discoveries have helped lead to the founding of Otologic Pharmaceutics, Inc.